Akèy › Kansè vejik › North Carolina

Etid klinik pou Kansè vejik nan North Carolina

26 etid pou Kansè vejik ap chèche patisipan nan sit nan North Carolina.

Vil nan North Carolina

Tèks ofisyèl etid la (Anglè)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

AdventHealth Infusion Center Asheville, Asheville
Southeastern Medical Oncology Center-Clinton, Clinton
AdventHealth Infusion Center Haywood, Clyde
ak 6 plis

Ap rekriteEtid obsèvasyonVolontè an sante akeyi

Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06770582

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Margaret R Pardee Memorial Hospital, Hendersonville

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Duke Cancer Center Cary, Cary
Duke University Medical Center (location of scans), Durham
Duke University Medical Center - Duke University Hospital (location of scans), Durham
ak 5 plis

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07421700

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Biorepository and Precision Pathology Center (BRPC), Durham
Duke Cancer Institute, Durham
Substrate Services Core Research Support (SSCRS), Durham

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07206225

DESTINY-PANTUMOUR04

Research Site, Durham
Research Site, Wilson

Ap rekriteEtid obsèvasyon

Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

WakeMed Raleigh Campus ( Site 0811), Raleigh

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07419295

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Levine Cancer Institute, Charlotte
Oncology Specialists of Charlotte, Charlotte
Wake Forest Baptist Health, Winston-Salem

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Carolina Biooncology Institute, Huntersville

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Duke University Medical Center - Duke Cancer Center, Durham

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07217171

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

UNC- Chapel Hill, Chapel Hill

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

University of North Carolina, Chapel Hill
Atrium Health/Levine Center, Charlotte
Associated Urologist of North Carolina (Solaris), Raleigh

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06567743

The Vanguard Study: Testing a New Way to Screen for Cancer

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Durham VA Medical Center, Durham

Ap rekriteVolontè an sante akeyi

Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

University of North Carolina (UNC) - Chapel Hill, Chapel Hill

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05614739

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Research Site, Chapel Hill

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07129993

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University Medical Center, Durham

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07097142

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

UNC Chapel Hill Hospital, Chapel Hill
Duke Health - Duke Cancer Center, Durham
Associated Urologists of North Carolina, Raleigh

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT04752722

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

University of North Carolina, Chapel Hill

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07225127

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem

Ap rekriteFaz 2

Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill
Carolinas Medical Center (biopsy only), Charlotte
ak 10 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT04879329